ArticleRSC chemical biology2026
Tuning potency for precision: the role of the G4-ligand in G4-ligand conjugated oligonucleotides targeting individual G-quadruplex DNA structures.
Article in RSC chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual recognition drives site-directed G-quadruplex stabilization: Oligonucleotide design in G4 ligand-oligonucleotide conjugates.Molecular therapy. Nucleic acids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The non-B DNA secondary structure known as G-quadruplex (G4) DNA can form in gene-regulatory regions of the human genome. Organic small molecules, so called G4-ligands, which bind and stabilize G4 DNA structures, have emerged as potential therapeutic agents and as chemical probes to study the cellular functions of these secondary DNA conformations. A major challenge, however, is their lack of selectively recognising different G4 structures, which hampers both their further development as therapeutics and their utility as research tools. This limitation can be addressed by linking the G4-ligand to a guide oligonucleotide, complementary to the flanking sequence of the target G4, a strategy called G4-ligand-conjugated oligonucleotides (GL-Os). Here, the G4-ligand used in the GL-O strategy is investigated by altering its physiochemical properties, including size and charge, and evaluating its potency using biochemical and biological assays. The results reveal a strong influence of the G4-ligand on the conjugates' ability to bind and stabilize the target G4 DNA. In particular, a larger and charged G4-ligand enhances both binding and stabilization of the target. However, increasing the G4-ligand potency may also increase off-target G4 binding, highlighting the need for a balanced G4-ligand potency to ensure high GL-O specificity for individual G4 structures.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.